NRBO | NeuroBo Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.3300 - 2.4400
52 Week Range	2.0400 - 6.75
Beta	-0.28
Implied Volatility	661.02%
IV Rank	77.94%
Day's Volume	12,978
Average Volume	42,680
Shares Outstanding	8,616,010
Market Cap	20,333,784
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-08-05

Valuation
Profitability
Growth
Health
P/E Ratio	-0.55
Forward P/E Ratio	N/A
EPS	-4.29
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	NRBO

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

NRBO's peers: ADIL, ADTX, APM, APVO, ATXI, DRUG, EDSA, EYEG, GTBP, HOTH, LIXT, MBIO, NLSP, NRSN, PSTV, QNRX, TENX, TTNP, VTVT, WINT, VRAX

*Chart delayed

Analyzing fundamentals for NRBO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see NRBO Fundamentals page.

Watching at NRBO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on NRBO Technicals page.